Presentations include new post-hoc analysis of data from phase 3
LUNAR trial in metastatic non-small cell lung cancer
Novocure (NASDAQ: NVCR) today announced its participation in the
upcoming International Association for the Study of Lung Cancer
(IASLC) 2023 World Conference on Lung Cancer (WCLC) from September
9 – 13, 2023 in Singapore. Novocure will take part in presentations
and symposia throughout the event and will exhibit several posters
exploring the use of Tumor Treating Fields (TTFields) therapy in
the treatment of lung cancer, including a new post-hoc analysis of
data from its LUNAR trial in metastatic non-small cell lung
cancer.
The LUNAR trial was designed to evaluate the use of TTFields
therapy together with standard systemic therapies for the treatment
of metastatic non-small cell lung cancer, following progression on
or after platinum-based therapy. The trial met its primary
endpoint, demonstrating a statistically significant and clinically
meaningful extension in overall survival (OS) for patients treated
with TTFields and standard systemic therapies, as well as a
pronounced extension in OS for patients randomized to receive
physician’s choice immune checkpoint inhibitor (ICI) together with
TTFields.
In a new post-hoc analysis of data from the LUNAR trial,
researchers reviewed survival patterns of patients with known Tumor
Proportion Scores (TPS) randomized to receive ICI together with or
without TTFields. Among patients with TPS >1%, median OS for patients treated with
TTFields therapy and ICI (n=22) was 23.6 months compared to 10.5
months for patients treated with ICI alone (n=26; HR: 0.49,
P=0.045).
Further analysis shows evidence of a relationship between
increasing PD-L1 expression and improved survival outcomes. In
patients with TPS 1–49%, median OS was 19.0 months for patients
treated with TTFields therapy and ICI (n=17), compared to 9.7
months for patients treated with ICI alone (n=18; HR: 0.55,
P=0.14). In patients with TPS >50%,
median OS was not reached for patients treated with TTFields
therapy and ICI (n=5) compared to 30.0 months for patients treated
with ICI alone (n=8; HR: 0.17, P=0.07).
These data will be presented on September 12, 2023 at 2:30 p.m.
UTC+8 by primary investigator Ticiana Leal, M.D., a researcher and
medical oncologist at Winship Cancer Institute of Emory University
and associate professor and director of the Thoracic Medical
Oncology Program in the Department of Hematology and Medical
Oncology at Emory University School of Medicine in Atlanta.
“This analysis further elucidates the promising results from the
LUNAR trial and the potential benefit of utilizing TTFields therapy
for the treatment of metastatic non-small cell lung cancer,” Dr.
Leal said. “I look forward to sharing these data with the global
thoracic oncology community and continuing to analyze the data from
this impactful study.”
Novocure’s presence at the 2023 WCLC will also include:
- An Industry Sponsored Symposium: A Spotlight on Tumor Treating
Fields in Thoracic Oncology, on September 10 at 6:30 p.m.
UTC+8
- A poster displayed in the Exhibit Hall on September 10 from
5:30-7:30 p.m. UTC+8: P1.12-10 – Sensitization of Cancer Cells to
Tumor Treating Fields (TTFields) via Inhibition of the PI3K/AKT
Signaling Pathway
- Three ePosters on demand:
- EP02.02-02 – Transcriptomic Response to Tumor Treating Fields
(TTFields) Across Tumor Types
- EP09.02-06 – Long-term Efficacy of Tumor Treating Fields
(TTFields 150 kHz) in metastatic NSCLC: A Case Report
- EP17.03-02 – Utilities Used in HTAs in mNSCLC Following
Progression on or After Platinum-Based Chemotherapy
In addition, Novocure is partnering with the IASLC, host of the
WCLC, to provide research opportunities to investigators worldwide
who are conducting innovative research on TTFields in the treatment
of non-small cell lung cancer and other thoracic malignancies.
These grants offer $100,000 to fund projects to be completed in a
two-year timeframe.
“We are honored to partner with the IASLC in their mission to
study and eradicate lung cancer and other thoracic malignancies,”
said Moshe Giladi, Ph.D., Novocure’s Chief Science Officer. “We
look forward to supporting researchers and together expanding
understanding of how TTFields therapy can be beneficial in the
treatment of these diseases.”
To learn more about these grants, please visit
https://iaslc.secure-platform.com/researchgrants/page/Grant_Guidelines/Partner_Grants/IASLC_Novocure_Grants.The
application deadline is noon MDT on October 9, 2023.
About LUNAR
LUNAR was a phase 3 trial testing the safety and effectiveness
of TTFields therapy when used together with ICI or docetaxel versus
ICI or docetaxel alone for patients with metastatic NSCLC who
progressed during or after platinum-based therapy. The trial met
its primary endpoint, exhibiting a statistically significant and
clinically meaningful improvement in median OS when TTFields
therapy was added to standard therapies. Patients randomized to
receive TTFields therapy together with standard therapies (n=137)
demonstrated median OS of 13.2 months compared to 9.9 months in
patients treated with standard therapies alone (n=139; HR: 0.74,
P=0.035).
The trial also demonstrated a statistically significant and
clinically meaningful improvement in median OS when TTFields
therapy was added to ICI. Patients randomized to receive TTFields
therapy and physician’s choice ICI (n=66) demonstrated a median OS
of 18.5 months versus a median OS of 10.8 months in patients
treated with ICIs alone (n=68; HR=0.63; P=0.03). Patients
randomized to receive TTFields therapy and docetaxel (n=71) had a
positive survival trend with a median OS of 11.1 months vs 8.7
months in patients treated with docetaxel alone (n=71). TTFields
therapy was well-tolerated with no added systemic toxicities and
few grade 3 (no grade 4 or 5) device-related adverse events.
TTFields therapy is intended principally for use with other
concomitant standard therapies, and LUNAR was designed to generate
data that contemplates multiple outcomes, all of which Novocure
believes will be clinically meaningful.
About NSCLC
Lung cancer is the most common cause of cancer-related death
worldwide, and NSCLC accounts for approximately 85% of all lung
cancers. It is estimated that approximately 193,000 patients are
diagnosed with NSCLC each year in the U.S. Physicians use different
combinations of surgery, radiation and pharmacological therapies to
treat NSCLC, depending on the stage of the disease. Surgery, which
may be curative in a subset of patients, is usually used in early
stages of the disease. Since 1991, radiation with a combination of
platinum-based chemotherapy drugs has been the first-line standard
of care for locally advanced or metastatic NSCLC. Certain immune
checkpoint inhibitors have been approved for the first-line
treatment of NSCLC and the standard of care in this setting appears
to be evolving rapidly. The standard of care for second-line
treatment is also evolving and may include platinum-based
chemotherapy for patients who received immune checkpoint inhibitors
as their first-line regimen, docetaxel, immune checkpoint
inhibitors or pemetrexed. It is estimated that approximately 46,000
patients receive second-line treatment for metastatic NSCLC each
year in the U.S.
About Novocure
Novocure is a global oncology company working to extend survival
in some of the most aggressive forms of cancer through the
development and commercialization of its innovative therapy, Tumor
Treating Fields. Novocure’s commercialized products are approved in
certain countries for the treatment of adult patients with
glioblastoma, malignant pleural mesothelioma and pleural
mesothelioma. Novocure has ongoing or completed clinical trials
investigating Tumor Treating Fields in brain metastases, gastric
cancer, glioblastoma, liver cancer, non-small cell lung cancer,
pancreatic cancer and ovarian cancer.
Headquartered in Root, Switzerland and with a growing global
footprint, Novocure has regional operating centers in Portsmouth,
New Hampshire and Tokyo, as well as a research center in Haifa,
Israel. For additional information about the company, please visit
Novocure.com and follow @Novocure on LinkedIn and Twitter.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, clinical trial progress, development of
potential products, interpretation of clinical results, prospects
for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage,
collections from third-party payers and other statements regarding
matters that are not historical facts. You may identify some of
these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar
meaning. Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, environmental, regulatory and
political conditions as well as issues arising from the COVID-19
pandemic and other more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on February 23, 2023, and subsequent filings with the U.S.
Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may
prove to be incorrect. Therefore, you should not rely on any such
factors or forward-looking statements. Furthermore, Novocure does
not intend to update publicly any forward-looking statement, except
as required by law. Any forward-looking statements herein speak
only as of the date hereof. The Private Securities Litigation
Reform Act of 1995 permits this discussion.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230908394524/en/
Investors: Ingrid Goldberg investorinfo@novocure.com
610-723-7427
Media: Leigh Labrie media@novocure.com 610-723-7428
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2024 to May 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From May 2023 to May 2024